190 related articles for article (PubMed ID: 34851506)
21. The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.
Kogure M; Takawa M; Saloura V; Sone K; Piao L; Ueda K; Ibrahim R; Tsunoda T; Sugiyama M; Atomi Y; Nakamura Y; Hamamoto R
Neoplasia; 2013 Nov; 15(11):1251-61. PubMed ID: 24339737
[TBL] [Abstract][Full Text] [Related]
22. Histone methylatic modification mediates the tumor-suppressive activity of curcumol in hepatocellular carcinoma via an Hotair/EZH2 regulatory axis.
Tian NN; Zheng YB; Li ZP; Zhang FW; Zhang JF
J Ethnopharmacol; 2021 Nov; 280():114413. PubMed ID: 34265379
[TBL] [Abstract][Full Text] [Related]
23. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
24. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
[TBL] [Abstract][Full Text] [Related]
25. Regulation of histone methylation by automethylation of PRC2.
Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
[TBL] [Abstract][Full Text] [Related]
26. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
Huang B; Huang M; Li Q
Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression.
Guigon CJ; Kim DW; Zhu X; Zhao L; Cheng SY
Endocrinology; 2010 Nov; 151(11):5528-36. PubMed ID: 20844001
[TBL] [Abstract][Full Text] [Related]
28. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
29. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma.
Sanna L; Marchesi I; Melone MAB; Bagella L
J Cell Physiol; 2018 Sep; 233(9):6508-6517. PubMed ID: 29574790
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
[TBL] [Abstract][Full Text] [Related]
31. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
32. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
Yang F; Lv LZ; Cai QC; Jiang Y
World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
Zhou M; Zhang XY; Yu X
Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma.
Zhang X; Zhang X; Wang T; Wang L; Tan Z; Wei W; Yan B; Zhao J; Wu K; Yang A; Zhang R; Jia L
Cancer Lett; 2018 Jul; 426():98-108. PubMed ID: 29653269
[TBL] [Abstract][Full Text] [Related]
35. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
[TBL] [Abstract][Full Text] [Related]
36. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
[TBL] [Abstract][Full Text] [Related]
37. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
Zhang T; Gong Y; Meng H; Li C; Xue L
Clin Epigenetics; 2020 May; 12(1):72. PubMed ID: 32448308
[TBL] [Abstract][Full Text] [Related]
38. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.
Xie CR; Li Z; Sun HG; Wang FQ; Sun Y; Zhao WX; Zhang S; Zhao WX; Wang XM; Yin ZY
Oncotarget; 2015 Dec; 6(38):40940-52. PubMed ID: 26517514
[TBL] [Abstract][Full Text] [Related]
39. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
[TBL] [Abstract][Full Text] [Related]
40. SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation.
Wang P; Zhao L; Rui Y; Ding Y
Cancer Gene Ther; 2023 Apr; 30(4):575-581. PubMed ID: 36127410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]